01 / 04
“Working with Dominic transformed our marketing approach. Their creativity and strategic insight boosted our brand visibility and engagement beyond expectations, driving measurable growth, increasing loyalty all project.’’
James Carter
Head of Marketing, StellarTech Solutions
04 / 04
“Partnering with Aisha was pivotal for our social media initiatives. Her expertise in trend analysis and campaign execution led to record-breaking follower growth and brand interactions.”
Michael Thompson
Social Media Director, Trendsetters Inc.
Pharming in focus
Pharming Group is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases with significant unmet need. We focus on immunological and genetic conditions where our scientific and commercial expertise can help advance care over the long term.
Our Annual Report is intended for shareholders, investors and financial media.
Our Annual Report is intended for shareholders, investors and financial media.
CHAIRMAN’S STATEMENT
Slide 2
Pharming enters its next phase with strong foundations in place, clearer priorities and increasing momentum. We look ahead with confidence in Pharming’s direction, in the strength of its people and capabilities, and in its ability to deliver meaningful impact for rare disease patients while creating long-term value.
Richard Peters
Chairman of the Board of Directors
© David van Dam | de Beeldunie
Chief Executive Officer's statement
Building a leading global rare disease company
2025 was a defining year for Pharming and reflects the focus and discipline our teams have brought to executing our strategy. Entering 2026, our priorities are clear: reinforce RUCONEST® as a cornerstone on-demand therapy for difficult to treat HAE patients, accelerate Joenja®’s expansion, and advance our pipeline to sustain our growth and broaden our impact in rare disease.
Fabrice Chouraqui
CEO Pharming
Chief Executive Officer's statement
Building a leading global rare disease company
2025 was a defining year for Pharming and reflects the focus and discipline our teams have brought to executing our strategy. Entering 2026, our priorities are clear: reinforce RUCONEST® as a cornerstone on-demand therapy for difficult to treat HAE patients, accelerate Joenja®’s expansion, and advance our pipeline to sustain our growth and broaden our impact in rare disease.
Fabrice Chouraqui
CEO Pharming
2025 at a glance
Financial information
In millions US$
Total revenues
376.1
2024: 297.2
27%
Overall cash and
marketable securities
marketable securities
181.1
2024: 169.4
7%
RUCONEST® revenues
317.9
2024: 252.2
26%
Joenja® revenues
58.2
2024: 45.0
29%
March
Abliva AB acquisition completed, adds napazimone (KL1333) for primary mitochondrial diseases
Australia TGA approval of Joenja® for APDS (12+)
First patient dosed in Phase II study for leniolisib in CVID with immune dysregulation
April
Positive NICE recommendation & launched Joenja® for APDS (12+) in the U.K. (England and Wales)
Wave 2 of recruitment started in pivotal FALCON study for napazimone (KL1333) in PMD
September
Promoted to the Euronext AMX® index
October
US FDA Acceptance & Priority Review of leniolisib sNDA for APDS (4-11 years)
December
Scottish Medicines Consortium (SMC) issued its ultra-orphan assessment for Joenja®
"Living with APDS while working in healthcare education gives me a unique perspective. I see how awareness shapes outcomes, which is why I'm passionate about teaching others, advancing understanding, and helping ensure patients are recognized, supported and cared for sooner."
Annie
Living with APDS
Strategic Business Review
In 2025 we strengthened our position as a growing rare disease company, delivering robust commercial performance alongside continued pipeline execution. This progress reflects a disciplined strategy focused on meaningful patient impact today and long-term growth over time.
Our vision is to develop a leading global rare disease company with a diverse portfolio and presence in large markets, leveraging proven and efficient clinical development, supply chain, and commercial infrastructure.
Commercial
Pipeline
Sustainability
Throughout 2025, we continued to leverage the work already invested over the past three years and continued to shape our sustainability program towards delivering the benefits of sustainability, beyond compliance.
"With the right plan, I've learned that I can live beyond HAE"
Noah
Living with HAE
Downloads
External links
View Form 20-F (coming soon)
View Form 20-F
View Form (20-F)
